A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer

Iaffaioli, Rosario Vincenzo; Tortoriello, A.; Facchini, Gaetano; Santangelo, Michele; Sena, Gabriele De; Gesue, G.; Bucci, Luigi; Scaramellino, G.; Anastasio, Elana; Finizio, A

doi:10.1038/bjc.1995.496

Cited by 24 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vinorelbine also has demonstrated significant antitumor activity against breast carcinoma when combined with other agents such as doxorubicin, [17][18][19] epirubicin, 20,21 5-fluorouracil (5-FU), [22][23][24] mitomycin C, [25][26][27][28][29] cisplatin, 30,31 and carboplatin. 32 Paclitaxel, conversely, promotes and stabilizes polymerized tubulin into nonfunctional microtubule bundles and therefore blocks the cells in the G2/Mphase of the cell cycle. It has proven activity in various solid tumors, including breast carcinoma.…”

mentioning

confidence: 99%

Phase I study of vinorelbine and paclitaxel by 3‐hour simultaneous infusion with and without granulocyte colony‐stimulating factor support in metastatic breast carcinoma

Ibrahim

Buzdar

Valero

et al. 2001

Cancer

View full text Add to dashboard Cite

mentioning

confidence: 99%

Phase I study of vinorelbine and paclitaxel by 3‐hour simultaneous infusion with and without granulocyte colony‐stimulating factor support in metastatic breast carcinoma

Ibrahim

Buzdar

Valero

et al. 2001

Cancer

View full text Add to dashboard Cite

“…There has been one prior published study applying the combination of carboplatin and vinorelbine [29]. However, no attempt was made to define the MTD of the combination and drug doses were selected rather arbitrarily based on reasonably tolerated doses of the drugs from other single agent or two-drug combination studies (vinorelbine 30 mg/m 2 days 1 + 8; carboplatin 250 mg/m 2 day 1) in a phase II evaluation of the regimen [29].…”

Section: Discussionmentioning

confidence: 99%

Phase I Study of Vinorelbine and Carboplatin Combination in Patients with Taxane and Anthracycline Pretreated Advanced Breast Cancer

Kosmas

Agelaki²,

Giannakakis³

et al. 2002

Oncology

View full text Add to dashboard Cite

Aim: To define the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of the carboplatin-vinorelbine combination in pretreated patients with advanced breast cancer. Patients and Methods: Patients with histologically confirmed metastatic breast cancer relapsing or progressing after prior taxane and anthracycline containing chemotherapy were enrolled. Cohorts of 3–6 patients were treated at successive dose levels (DLs) with escalated doses of carboplatin [range, area under the curve (AUC) 4–6] on day 1 and vinorelbine (range, 20–35 mg/m²) on days 1 + 8 recycled every 28 days. Results: Twenty-seven patients with a median age of 58 years and performance status (WHO) of 0–2 were treated at 6 DLs. All patients were assessable for toxicity and 20 for response. DLT was reached at carboplatin 6 AUC and vinorelbine 35 mg/m², and therefore, this was considered as the MTD. Prophylactic G-CSF administration could not allow further dose escalation. The recommended dose for further phase II testing was defined at carboplatin 6 AUC on day 1 and vinorelbine 30 mg/m² on days 1 and 8. Among 98 administered treatment cycles 41 (42%) and 7 (7%) were complicated with grades 3 and 4 neutropenia and thrombocytopenia, respectively. Nonhematologic toxicities included grade 2 peripheral neuropathy in 3 cycles and grades 2 and 3 fatigue in 32 (32%). Conclusion: The present study determined the feasibility of the combination of carboplatin at AUC 6 (day 1) and vinorelbine at 30 mg/m² (days 1 and 8 ) without G-CSF support in patients with taxane and anthracycline pretreated advanced breast cancer. Phase II studies at these doses should follow in order to determine the activity of the regimen.

show abstract

“…The conclusion was that this regimen is considered active as a second-line therapy in MBC [139]. In a study performed by Iaffaioli et al [140], 41 patients with MBC were given carboplatin and vinorelbine as second-line therapy. The RR was 46% (range 26–56%).…”

Section: Experience With Combination Chemotherapymentioning

confidence: 99%

“…The RR was 46% (range 26–56%). Myelotoxicity was the most frequent side effect, with grade III/IV leukopenia seen in 46% of patients [140]. In a phase I trial on patients with refractory solid tumors, 38 patients were treated with vinorelbine and oxaliplatin.…”

Section: Experience With Combination Chemotherapymentioning

confidence: 99%

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Shamseddine¹,

Farhat²

2011

Chemotherapy

View full text Add to dashboard Cite

The role of platinum-based compounds (PBCs) in the treatment of metastatic breast cancer (MBC) has been extensively studied. As single agents, high response rates have been observed in first-line therapy, while results in pretreated patients were discouraging. Regimens containing cisplatin/carboplatin together with taxanes showed the highest efficacy and safety as both first-line and second-line therapy. When administered with vinorelbine, the combination was also active and well tolerated in anthracycline- and taxane-pretreated patients. Combining PBCs with etoposide or nucleoside analogues showed moderate activity, yet high toxicity in the case of etoposide. The overall results for the combination with anthracyclines were disappointing. Addition of trastuzumab to PBC combinations showed remarkable activity and good tolerability in patients with HER2/neu overexpression. The use of cisplatin or carboplatin alongside novel targeted therapeutics for patients with triple-negative MBC seems promising and is being further evaluated. The use of PBCs against MBC requires careful patient selection and combination with the right chemotherapeutic agent.

show abstract

A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer

Cited by 24 publications

References 15 publications

Phase I study of vinorelbine and paclitaxel by 3‐hour simultaneous infusion with and without granulocyte colony‐stimulating factor support in metastatic breast carcinoma

Phase I study of vinorelbine and paclitaxel by 3‐hour simultaneous infusion with and without granulocyte colony‐stimulating factor support in metastatic breast carcinoma

Phase I Study of Vinorelbine and Carboplatin Combination in Patients with Taxane and Anthracycline Pretreated Advanced Breast Cancer

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Contact Info

Product

Resources

About